Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: Correlation with tumor markers α-fetoprotein and human chorionin gonadotropin

European Journal of Endocrinology

Volumn 159, Issue 3, 2008, Pages 317-327

  Fottner, Christian ^a   Sattarova, Sabina ^a   Hoffmann, Kerstin ^a   Spöttl, Gerald ^b   Weber, Matthias M ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C; THIOTEPA; TUMOR MARKER; AFP PROTEIN, HUMAN; IGFBP3 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOBLOTTING; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; TESTIS CANCER; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROTEIN PROCESSING; RECURRENT DISEASE; TESTIS TUMOR; UPREGULATION;

ADULT; ALPHA-FETOPROTEINS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECURRENCE; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 53249149658     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0033     Document Type: Article

References (47)

1. Bergstrom R, Adami HO, Mohner M, Zatonski W, Storm H, Ekbom A, Tretli S, Teppo L, Akre O & Hakulinen T. Increase in testicular cancer incidence in six European countries: a birth-cohort phenomenon. Journal of the National Cancer Institute 1996 88 727-733.
2. Horwich A, Shipley J & Huddart R. Testicular germ-cell cancer. Lancet 2006 367 754-765.
3. American joint Committee on Cancer: Manual for Staging Cancer. 5th ed. Chicago, III: American Joint Committee on Cancer; 1997
4. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmarmsberger C, Fossa SD, Skakkeback NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Kochrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C & European Germ Cell Cancer Consensus Group. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Annals of Oncology 2004 15 1377-1399.
5. Carver BS & Sheinfeld J. Germ cell tumors of the testis. Annals of Surgical Oncology 2005 12 871-880.
6. Bridges B & Hussain A. Testicular germ cell tumors. Current Opinion in Oncology 2007 19 222-228.
7. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Modern Pathology 2005 18 S51-S60.
8. Christoph F, Kempkensteffen C, Weikert S, Krause H, Schostak M, Miller K & Schrader M. Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors. Cancer Letters 2007 247 137-142.
9. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM & Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004 363 1346.
10. Czech MP. Signal transmission by the insulin-Re growth factors. Cell 1989 59 235-238.
11. Jones JI & Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995 16 3-34.
12. Baxter RC & Martin JL. Binding proteins for the insulin-like growth factors: structure, regulation and function. Progress in Growth Factor Research 1989 1 49-68.
13. Samani AA, Yakar S, LeRoith D & Brodt R The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews 2007 28 20-47.
14. Neuvians TP, Gashaw I, Hasenfus A, Häcker A, Winterhager E & Grobholz R. Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue. Neoplasia 2005 7 446-456.
15. Zhou J & Bondy C. Anatomy of the insulin-like growth factor system in the human testis. Fertility and Sterility 1993 60 897-904.
16. Vannelli BG, Barni T, Orplando C, Natali A, Serio M & Balboni GC. Insulin-like growth factor-I (IGF-1) and IGF-I receptor in human testis: an immunohistochemical study. International Journal of Andrology 1987 10 79-84.
17. Drescher B, Lauke H, Hartmann M, Davidoff MS & Zumkeller W. Immunohistochemical pattern of insulin-like growth factor (IGF) I, IGF II and IGF binding proteins 1 to 6 in carcinoma in situ of the testis. Molecular Pathology 1997 50 298-303.
18. Engstrom W Hopkins B & Schofield P. Expression of growth regulatory genes in primary human testicular neoplasms. International Journal of Andrology 1987 10 79-84.
19. Rajaram S, Baylink DJ & Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 1997 18 801-831.
20. Weber MM, Auernhammer CJ, Lee PD, Engelhardt D & Zachoval R. Insulin-like growth factors and insulin-like growth factor binding proteins in adult patients with severe liver disease before and after orthotopicliver transplantation. Hormone Research 2002 57 105-112.
21. Gerl A, Lamerz R, Mann K, Clemm C & Wilmanns W. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors? Anticancer Research 1997 17 3047-3049.
22. Weber MM, Simmler P, Fottner C & Engelhardt D. Insulin-like growth factor II (IGF-II) is more potent than IGF-I in stimulating cortisol secretion from cultured bovine adrenocortical cells: interaction with the IGF-I receptor and IGF-binding proteins. Endocrinology 1995 136 3714-3720.
23. Weber MM, Kiess W Beikler T, Simmler P. Reichel M, Adehmann B, Kessler U & Engelhardt D. Identification and characterization of insulin-like growth factor I (IGF-I) and IGF-II/mannosc-6-phosphate (IGF-II/M6P) receptors in bovine adrenal cells. European Journal of Endocrinology 1994 130 265-270.
24. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JKV & Sawyers CL. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and P13K/Akt pathway activation in ghoblastoma and prostate cancer. PNAS 2007 104 5563-5568.
25. Khandwala HM, McCutcheon IE, Flyvbjerg A & Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Reviews 2000 21 215-244.
26. Boulle N, Logie A, Gicquel C, Perin L & Le Bouc Y, Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 1713-1720.
27. Zavos C, Andreadis C, Diamantopoulos N & Mouratidou D. A hypothesis on the role of insulin-like growth factor I in testicular germ cell tumours. Medical Hypotheses 2004 63 511-514.
28. Frommer KW, Reicherimiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G & Elmlinger MW IGF-independent effects of 1GFBP-2 on the human breast cancer cell line Hs578T. Journal of Molecular Endocrinology 2006 37 13-23.
29. Van Gurp RJ, Oosterhuis JW Kalscheuer V, Mariman EC & Looijenga LH. Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. Journal of the National Cancer Institute 1994 86 1070-1075.
30. Holly J & Perks C. The role of Insulin-like growth factor binding proteins. Neuroendocrinology 2006 83 154-160.
31. Pollak NM, Schernhammer ES & Hankinson SE. Insulin-like growth factors and cancer. Nature Reviews. Cancer 2004 14 277-286.
32. Hoeflich A, Reisinger R, Lahm H, Kiess W Blum WE Kolb HJ, Weber MM & Wolf E. Insulin-like growth factor-binding protein 2 in tumorigenesis - protector or promoter? Cancer Research 2001 61 8601-8610.
33. Wang D, Nagpal ML, Lin T, Shimasaki S & Ling N. Insulin-like growth factor-binding protein-2: the effect of human chorionic gonadotropin on its gene regulation and protein secretion and its biological effects in rat Leydig cells. Molecular Endocrinology 1994 8 69-76.
34. Besnard V, Corroyer S, Trugnan G, Chadelat K, Nabeyrat E, Cazals V & Clement A. Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochimica et Biophysica Acta 2001 1538 47-58.
35. Cazals V, Nabeyrat E, Corroyer S, de Keyzer Y & Clement A. Role for NF-KB in mediating the effects of hyperoxia on IGP-binding protein 2 promoter activity in lung alveolar epithelial cells. Biochimica et Biophysica Acta 1999 1448 349-362.
36. Perks CM, Vernon EG, Rosendahl AH, Tonge D & Holly JM. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 2007 26 5966-5972.
37. Moorehead RA, Hojilla CV, De Belle I, Wood GA, Fata JE, Adamson ED, Watson KL, Edwards DR & Khokha R. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. Journal of Biological Chemistry 2003 278 50422-50427.
38. Kang-Park S & Lee YL PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downrcgulates IGF-II expression in hepatoma cells. FEBS Letters 2003 545 203-208.
39. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN & Zhang W. Insulin-like growth factor binding protein 2 promotes glioma development and progression. PNAS 2007 104 11736-11741.
40. Di Vizio D, Cito L, Boccia A, Chieffi P, Insabato L, Pettinato G, Motti ML, Schepis F, D'Amico W, Fabiani E Tavernise B, Venuta S, Fusco A & Viglietto G. Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 2005 24 1882-1894.
41. Helle SI, Geisler S, Aas T, Paulsen T, Holly JM & Lønning PE. Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. British Journal of Cancer 2001 85 74-77.
42. Gronbaek H, Tanos V, Meirow D, Peretz T, Raz I & Flyvbjerg A. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Research 2003 23 2815-2820.
43. Baciuchka M, Remacle-Bonnet M, Garrouste F, Favre R, Sastre B & Pommier G. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer: possible association with the metastatic potential of the tumor. International Journal of Cancer 1998 79 460-467.
44. Crown AL, Cottle K, Lightman SL, Falk S, Mohamed-Ali V, Armstrong L, Millar AB & Holly IM. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clinical Endocrinology 2002 56 723-733.
45. Mitsui Y, Mochizuki S, Kodama T, Shimoda M, Ohtsuka T, Shiomi T, Chijiiwa M, Ikeda T, Kitajima M & Ohtsuka Y. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Research 2006 66 9913-9920.
46. Angelloz-Nicoud P, Lalou C & Binoux M. Prostate carcinoma (PC-3) cell proliferation is stimulated by the 22-25-kDa proteolytic fragment (1-160) and inhibited by the 16-kDa fragment (1-95) of recombinant human insulin-like growth factor binding protein-3. Growth Hormone and IGF Research 1998 8 71-75.
47. Martin DC, Fowlkes JL, Babic B & Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. Journal of Cell Biology 1999 146 881-892.